The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Private equity funds grab smaller slice of M&A deals

Fri, 28th Mar 2014 00:00

By Freya Berry

LONDON, March 28 (Reuters) - Buyout firms are finding itharder to take part in mergers and acquisitions as the lure ofstronger equity markets persuades more funds seeking to exitassets to try their luck with a public share sale or turn tocash-rich corporate buyers.

Private equity-backed mergers and acquisitions (M&A) fell byalmost a third to $55.2 billion from a year ago, Thomson Reutersquarterly data showed on Friday.

European private equity firms accounted for 8 percent of M&Adeals in the year to date, down from 10 percent from the sameperiod last year and the lowest since 2011, although the valueof private equity-backed deals did rise in the region.

"The bottom line is that in many sectors private equity isstruggling to compete with the public markets," said JamesSimpson, Head of Sponsor M&A at UBS. "Assets that wouldnaturally have come to private equity are going to IPO."

The MSCI World Price Index surged 24 percentlast year. That has brought a rash of companies to market asthey seek to capitalise on buoyant public interest, limiting thedeals available for buyout firms.

Private equity firms are also grappling with asset priceinflation.

Valuations have risen, partly due to a scarcity of assets,because of companies turning to IPOs, but also due to a growingamount of undeployed fund capital which leaves private equityfunds paying out more as they hunt for ways to spend cash.

A report by Bain & Company this month found that undeployedcapital, or dry powder, hit $1 trillion at the end of 2013,pushed up by investors seeking returns in a world of lowinterest rates.

"Multiples have gone up," Simpson said. "You have toacclimatise to paying bigger prices, and that takes a bit oftime."

As well as expensive assets, funds are also shying away fromcompetition with huge corporate cashpiles built up since thefinancial crisis.

Last year, GlaxoSmithKline scrapped a plan to sellits drinks businesses Lucozade and Ribena in an auction whichwould have included private equity firms when Japan's SuntoryBeverage & Food muscled in.

"Whilst (investors) would continue to say this is afantastic environment in which to exit businesses, it's actuallystill proving to be a challenging environment in which to deploynew capital," said Alasdair Warren, head of European FinancialSponsors Group at Goldman Sachs.

"The IPO markets are so strong and the multiples are sohigh, that it is very difficult for sponsors to compete."

But despite the squeeze, private equity firms are confidentthat the rush to IPO will not last forever.

"It is likely that the IPO markets will remain open for sometime but how long it will last is hard to tell," said LionelAssant, Senior Managing Director and European Head of PrivateEquity at Blackstone.

"Public markets rightly demand a proven management team anda clear strategy for growth from any company floating."

Goldman Sachs led the global rankings for M&A advisorbanks with a 46.3 percent market share, while JP Morgan was top for European deals with a 32.4 percent market share, thedata showed.

There have been 271 deals in Europe so far, an increase of6.7 percent year-on-year. But the value of transactionsincluding net debt has soared 24 percent to $12.9 billion overthe same period, the data showed. (Editing by Elaine Hardcastle)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.